Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 30,000 shares of the business’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $79.00, for a total value of $2,370,000.00. Following the completion of the sale, the executive vice president now directly owns 57,114 shares in the company, valued at $4,512,006. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Gilead Sciences, Inc. (GILD) opened at $81.17 on Friday. The company has a market capitalization of $106,000.00, a price-to-earnings ratio of 9.23, a P/E/G ratio of -1.71 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $86.27.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. Gilead Sciences’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.75 earnings per share. equities analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
GILD has been the subject of several recent analyst reports. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price target for the company in a research note on Friday, October 13th. Berenberg Bank set a $96.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. BMO Capital Markets decreased their price target on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. Credit Suisse Group restated a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a research note on Thursday, December 7th. Finally, Mizuho boosted their price target on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eighteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $85.53.
A number of institutional investors have recently bought and sold shares of GILD. FMR LLC increased its position in Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after buying an additional 258,005 shares in the last quarter. Vanguard Group Inc. increased its position in Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares in the last quarter. Northern Trust Corp increased its position in Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after buying an additional 116,780 shares in the last quarter. Toronto Dominion Bank increased its position in Gilead Sciences by 19.0% in the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock worth $33,445,000 after buying an additional 75,364 shares in the last quarter. Finally, Fagan Associates Inc. increased its position in Gilead Sciences by 2.6% in the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock worth $2,341,000 after buying an additional 845 shares in the last quarter. Institutional investors own 75.95% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.